

Technology Advisory Committee C Interests Register

Topic [ID4045]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	TAC C Committee Member	Financial Interests	Michael Chambers has participated in an advisory panel for Pfizer (manufacturer of possible comparator) in an unrelated disease area (prostate cancer)	14/11/2023	It was agreed that Michael Chambers' declaration would not prevent him from participating in discussions on this appraisal.
Dr Kate Ren	TAC C Committee Member	Financial Interests	Dr Kate Ren has provided statistical methodology consultancy service for Pfizer (Tofacitinib for patients with moderate-to-severe ulcerative colitis).	14/11/2023	It was agreed that Dr Kate Ren's declaration would not prevent her from participating in discussions on this appraisal.
Dr Steven Lloyd	TAC C Committee Member	Financial Interests	Dr Steven Lloyd has done paid work by AbbVie on immunology referral pathways.	14/11/2023	It was agreed that Dr Steven Lloyd's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Satish Venkateshan - New committee member (observing)	TAC C Committee Member	Direct - Financial Interests	Dr Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish also owns shares in the company and has stock options. Regeneron is developing Odronextamab CD20xCD3 bispecific antibody and has filed for EMA approval to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies.	14/11/2023	It was agreed that Dr Satish Venkateshan's declaration would prevent him from participating in discussions on this appraisal.
Associate Professor David Lewis	Clinical expert	Direct – Financial	David Lewis has received payment to attend Abbvie/Genmab hosted clinical advisory board meeting for which David was remunerated. David has also reviewed health economic data that in parts contributes to this submission. I was remunerated for this meeting.	28/02/2023	It was agreed that David Lewis's declaration would prevent him from providing expert advice to the committee.
Dr Wendy Osborne	Clinical expert	Direct – Financial Interests	Dr Wendy Osborne has received speaker fees, advisory fees and travel support from AbbVie, Roche, Pfizer, Servier, Kite Gilead, Incyte	27/04/2023	It was agreed that Dr Wendy Osborne's declaration would prevent

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			and BMS Celgene which have all been declared on ABPI.		her from providing expert advice to the committee.